Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Primary completion pushed from Sep 2026 to Sep 2027
Also in this update: Study completion pushed from Mar 2027 to Mar 2028
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEarly Phase 1 NCT06398457 Registry history of NCT06398457 on ClinicalTrials.gov (opens the registry)